Skip to main content

Givlaari Prices, Coupons, Copay Cards & Patient Assistance

Givlaari (givosiran) is a member of the miscellaneous metabolic agents drug class and is commonly used for Porphyria.

The cost for Givlaari (189 mg/mL) subcutaneous solution is around $44,884 for a supply of 1 milliliter(s), depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

Givlaari is available as a brand name drug only, a generic version is not yet available. View generic Givlaari availability for more details.

Givlaari prices

Subcutaneous Solution

189 mg/mL

Givlaari subcutaneous solution

 from $44,884.15

for 1 milliliter(s)
Quantity Per unit Price
1 milliliter $44,884.15 $44,884.15

Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.

Givlaari Coupons, Copay Cards and Rebates

Givlaari offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.

Drugs.com Printable Discount Card

The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.

Print Free Discount Card

Note: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.

Givlaari Alnylam Commercial Copay Program

Eligible commercially insured patients may receive financial assistance for certain out-of-pocket costs.

Applies to:
Givlaari
Number of uses:
Contact the program

Form more information phone: 833-256-2748 or Visit website

Patient Assistance & Copay Programs for Givlaari

Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.

Provider: HealthWell Foundation Copay Program

Eligibility requirements:
  1. May have insurance
  2. Varies
  3. FDA Approved Diagnosis - See Program Website for Details
  4. The patient must also be residing in the US.
  5. This program provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. Also, for those who are eligible for health insurance, but cannot afford the insurance premium, the foundation may be able to help by paying some or all of the medical portion of insurance premiums. The patient is being treated for a specific disease for which funding is available and has insurance that covers the treatment for this disease. Call for most recent medications as the list is subject to change.
Applicable drugs:
  • Givlaari (givosiran) Injection; Subcutaneous

More information please phone: 800-675-8416 Visit Website

Provider: Alnylam Assist: GIVLAARI

Eligibility requirements:
  1. Must be uninsured or rendered uninsured
  2. Not disclosed
  3. FDA-approved diagnosis
  4. The patient must also be a US resident.
  5. This program also provides co-pay assistance for eligible patients. Contact the program for more details.
Applicable drugs:
  • Givlaari (givosiran) Injection; Subcutaneous

More information please phone: 833-256-2748 Visit Website

Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.